Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment
Authors:
Open Access
- 28 March 2019
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 23 (6) , 4111-4117
Abstract
The bone marrow (BM) microenvironment contributes to drug resistance in acute myeloid leukaemia (AML) and multiple myeloma (MM). We have shown that the critical drug metabolizing enzymes cytochrome P450 (CYP) 3A4 and cytidine deaminase (CDA) are highly expressed by BM stroma, and play an important role in this resistance to chemotherapy. However, what factors influence the chemoprotective capacity of the BM microenvironment, specifically related to CYP3A4 and CDA expression, are unknown. In this study, we found that the presence of AML cells decreases BM stromal expression of CYP3A4 and CDA, and this effect appears to be at least partially the result of cytokines secreted by AML cells. We also observed that stromal CYP3A4 expression is up‐regulated by drugs commonly used in AML induction therapy, cytarabine, etoposide and daunorubicin, resulting in cross‐resistance. Cytarabine also up‐regulated CDA expression. The up‐regulation of CYP3A4 associated with disease control was reversed by clarithromycin, a potent inhibitor of CYP3A4. Our data suggest that minimal residual disease states are characterized by high levels of stromal drug metabolizing enzymes and thus, strong microenvironment‐mediated drug resistance. These results further suggest a potential role for clinically targeting drug metabolizing enzymes in the microenvironment.Keywords
Funding Information
- National Institutes of Health (K08 HL127269, PO1 CA15396)
- Leukemia and Lymphoma Society (6473-15)
This publication has 48 references indexed in Scilit:
- Integrating pharmacogenetics into gemcitabine dosing—time for a change?Nature Reviews Clinical Oncology, 2011
- P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808Blood, 2010
- Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and PharmacokineticsClinical Pharmacology & Therapeutics, 2009
- The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndromesCancer, 2008
- Aberrant cytokine signaling in leukemiaOncogene, 2007
- Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621Journal of Clinical Oncology, 2004
- Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanismsLeukemia, 2003
- Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cellsJournal of Pharmaceutical Sciences, 2001
- The mechanism of cyclosporine toxicity induced by clarithromycinBritish Journal of Clinical Pharmacology, 1997
- Continuous growth and differentiation of human myeloid leukaemic cells in suspension cultureNature, 1977